What it is
Melanotan 2 (MT-2) is a synthetic peptide that mimics α-melanocyte-stimulating hormone (α-MSH). It is best known for stimulating melanin production and skin pigmentation, with secondary research interest in sexual function and appetite control. Effects are downstream of broad melanocortin receptor activation (MC1, MC3, MC4, MC5).
Mechanism of action
Non-selective melanocortin receptor agonist. MC1 activation drives melanin synthesis; MC4 activation underlies sexual arousal and appetite suppression; MC3/5 contribute to lipid and immune effects.
Half-life: ~30 minutes to a few hours, with prolonged tissue effects on pigmentation.
Evidence summary
Pilot Phase 1 work (1996) characterised the cyclic peptide pharmacology. Subsequent trials in psychogenic ED (1998), preformulation work, and recent appetite/dermatology research extend the profile, though MT-2 is unapproved.
Pantheon dosing guide
- Application
- Subcutaneous injection.
- BAC Water
- 3 ml
- Dose
- 5 units (166 mcg).
- Frequency & Cycle Length
- 1 to 3 times per week for up to 2 weeks, then reduce to once weekly.
- Timing
- Take on an empty stomach or with a light meal.
- Key Benefits
- Increases melanin production for a deeper tan. Supports the skin's natural defense against UV exposure. Promotes overall skin health. Often increase libido.
Additional research protocol context
The printed guide above is Pantheon's dosing reference. These broader research examples are provided as context and may use different schedules.
- Loading: 250–500 mcg subcutaneous daily until pigmentation onset
- Maintenance: 250–500 mcg, 1–3× weekly
- Apply standard sun-exposure for activation
Side effects & safety
- Nausea, flushing, appetite suppression early in cycle
- Spontaneous erections / yawning common (MC4 effects)
- Risk of new or darkening moles — dermatology monitoring advised
- • Personal or family history of melanoma
- • Multiple atypical nevi
Cited studies
- (1996). Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences (ScienceDirect).Read source ↗
- (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology.Read source ↗
- (1994). Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. Journal of Pharmaceutical Sciences.Read source ↗
- (2022). Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides.Read source ↗
- (2021). Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology.Read source ↗
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.